Archives of Clinical Infectious Diseases
Infectious Diseases and Tropical Medicine Research Center, SBUMS
Authors
1,*Streptokinase (SK) is most widely used for treatment of myocardial infarction, however, it is the most expensive thrombolytic agent. A major drawback to SK use is the widespread presence of antistreptokinase antibodies (Abs). These Abs cause allergic reactions and neutralize streptokinase therapeutic effects.
To produce an engineered variant of streptokinase being functional and less antigenic than the native molecule, we cloned and expressed streptokinase mutant gene lacking the C terminal 42 amino acids. Recombinant protein was confirmed by western blot analysis with anti T7 monoclonal antibodies.
pGEMEX-1 expression vector contains T7 gene 10 protein as fusion protein immediately down stream of T7 promoter and before multiple cloning site, streptokinase mutant gene was cloned after fusion protein.
We cloned and expressed mutant streptokinase gene, lacking the C-terminal 42 amino acids. If mut-C42 activity was less affected by neutralizing antibodies compared with native streptokinase, this engineered variant could be a preferred alternative to native streptokinase for thrombolytic therapy.
© 2008, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.
Molaee N, Abtahi H, Mossayebi G. Expression of recombinant streptokinase (SKA) of group A streptococci in E. coli. J Inflamm Dis. 2024;16(3):e155704. doi:
Mahboubi A, Sadjady SK, Mirzaei Saleh Abadi M, Azadi S, Solaimanian R. Biological Activity Analysis of Native and Recombinant Streptokinase Using Clot Lysis and Chromogenic Substrate Assay. Iran J Pharm Res. 2012;11(4):e125900. doi: https://doi.org/10.22037/ijpr.2012.1173
Aghaeepoor M, Akbarzadeh A, Kobarfard F, Shabani AA, Dehnavi E, et al. Optimization and High Level Production of Recombinant Synthetic Streptokinase in E. coli Using Response Surface Methodology. Iran J Pharm Res. 2019;18(2):e126223. doi: https://doi.org/10.22037/ijpr.2019.1100636
Qingxin Z, Jing H, Kaixia Y, Jian W, Yijun K, et al. Pectate Lyase Promoting Streptolysin O Expression in Escherichia coli and Strengthening Its Activity. Jundishapur J Microbiol. 2017;10(9):e14337. doi: https://doi.org/10.5812/jjm.14337
Farhangnia L, Ghaznavi- Rad E, Mollaee N, Abtahi H. Cloning, Expression, and Purification of Recombinant Lysostaphin From Staphylococcus simulans. Jundishapur J Microbiol. 2014;7(5):e10009. doi: https://doi.org/10.5812/jjm.10009
Last Update: 1 month ago
Last Update: 1 month ago
Last Update: 1 month ago
Last Update: 5 days ago
Last Update: 1 hour ago
Last Update: 2 days ago
